周日报道，Xenon公布的第3阶段X-SYS 2数据显示，Azetukalner在AAN 2026上将局灶性发作癫痫的每月癫痫发作频率降低了53.2%，而安慰剂降低了10.4%

2026-04-20 16:34

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points
X-TOLE2 data featured in the Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind period
Long-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in four participants achieving at least 24 months of seizure freedom
Real-world data reinforce the value of anti-seizure medications that do not require titration to reduce stress and simplify focal seizure management for both patients and physicians